OmniAb Q4 Revenue Plunges 22%, Misses Estimates; Net Loss Widens
Summary
OmniAb, Inc. reported a significant Q4 revenue decline of 22% year-over-year, reaching $8.4 million and missing analyst expectations of $9.003 million. The company's net loss also widened to $14.2 million from $13.1 million in the prior year. This substantial revenue miss and increased loss are material negative developments for the biotech platform. Furthermore, OmniAb provided 2026 revenue guidance of $25 million to $30 million, alongside operating expense forecasts of $80 million to $85 million, and an anticipated cash balance of $30 million to $35 million by year-end. Traders will be closely watching how these results and forward guidance impact the company's valuation and future growth prospects, especially given its relatively small market capitalization.
At the time of this announcement, OABI was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.6M. The 52-week trading range was $1.22 to $3.46. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.